The Food and Drug Administration’s approval of lecanemab, a new Alzheimer’s medication shown in clinical trials to reduce the disease slowly over time.
The results are based on the SURMOUNT-5 Phase 3b open-label clinical trial, in which the two incretin-based drugs were directly compared over a 72-week duration.
The Phase III POTOMAC trial evaluated the effectiveness of Imfinzi in combination with BCG therapy compared to BCG therapy alone in patients with high-risk NMIBC.
In a Phase 3 trial, investigational icotrokinra led to 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieving clear or almost clear skin specifically on those affected sites by Week 16.
The computer program forecasts individual strands of DNA building blocks (A, T, C, and G) needed to create desired patterns of gene expression in various types of cells.
Compared to existing CAR T treatments, the off-the-shelf experimental therapeutic CTX112TM may allow for quicker patient access.
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population.
Johnson & Johnson today announced significant long-term findings from the Phase 3 QUASAR study program, demonstrating that TREMFYA® (guselkumab) delivered sustained rates of clinical remission [Read More…]
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume [Read More…]
